Imbalanced NK cell subpopulations and TIGIT expression limit cetuximab efficacy in colorectal cancer: A promising target for treatment enhancement

Carmen Navarrete-Sirvent; Ana Mantrana; Aurora Rivas-Crespo; Alejandra Díaz-Chacón; Nerea M. Herrera-Casanova; María Teresa Sánchez-Montero; Marta Toledano-Fonseca; María Victoria García-Ortiz; María José Ortiz-Morales; Gema Pulido; Mª Teresa Cano; Auxiliadora Gómez-España; Rafael González-Fernández; Lionel Le Bourhis; Silvia Guil-Luna; Antonio Rodríguez-Ariza; Enrique Aranda

doi:10.1002/ctm2.70351

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (6) : e70351 DOI: 10.1002/ctm2.70351

LETTER TO THE JOURNAL

Imbalanced NK cell subpopulations and TIGIT expression limit cetuximab efficacy in colorectal cancer: A promising target for treatment enhancement

Author information +

History +

PDF

Cite this article

Download citation ▾

Carmen Navarrete-Sirvent, Ana Mantrana, Aurora Rivas-Crespo, Alejandra Díaz-Chacón, Nerea M. Herrera-Casanova, María Teresa Sánchez-Montero, Marta Toledano-Fonseca, María Victoria García-Ortiz, María José Ortiz-Morales, Gema Pulido, Mª Teresa Cano, Auxiliadora Gómez-España, Rafael González-Fernández, Lionel Le Bourhis, Silvia Guil-Luna, Antonio Rodríguez-Ariza, Enrique Aranda. Imbalanced NK cell subpopulations and TIGIT expression limit cetuximab efficacy in colorectal cancer: A promising target for treatment enhancement. Clinical and Translational Medicine, 2025, 15(6): e70351 DOI:10.1002/ctm2.70351

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Chen S, Li X, Chen R, Yin M, Zheng Q. Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model. Oncol Lett. 2016; 12(3): 1868-1876.

[2]	García-Foncillas J, Sunakawa Y, Aderka D, et al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front Oncol. 2019; 9: 849.

[3]	Al Obeed OA, Alkhayal KA, Al Sheikh A, et al. Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages. World J Gastroenterol. 2014; 20(48): 18390-18396.

[4]	Hamarsheh S, Groß O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020; 11(1): 5439.

[5]	Yang C, Tsaih SW, Lemke A, Flister MJ, Thakar MS, Malarkannan S. mTORC1 and mTORC2 differentially promote natural killer cell development. Elife. 2018; 7: e35619.

[6]	Merino AM, Kim H, Miller JS, Cichocki F. Unraveling exhaustion in adaptive and conventional NK cells. J Leukoc Biol. 2020; 108(4): 1361-1368.

[7]	Zhang P, Liu X, Gu Z, et al. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res. 2024; 12(1): 7.

[8]	Liang R, Zhu X, Lan T, et al. TIGIT promotes CD8⁺T cells exhaustion and predicts poor prognosis of colorectal cancer. Cancer Immunol Immunother. 2021; 70(10): 2781-2793.

[9]	Chauvin JM, Ka M, Pagliano O, et al. IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma. Clin Cancer Res. 2020; 26(20): 5520-5533.

[10]	Wang F, Hou H, Wu S, et al. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol. 2015; 45(10): 2886-2897.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.